News & Publications

News

Deals & Cases

BioVersys announces successful first closing of CHF 24.2 million Series C financing to develop clinical pipeline of novel AMR therapies

8 June 2022 – Walder Wyss advises BioVersys in connection with the CHF 24.2m Series C Financing.

BioVersys, a privately-held clinical stage, multi-asset Swiss pharmaceutical company focusing on research and development of therapies for life-threatening multidrug-resistant bacterial infections and targeted microbiome modulation, announced today that it has raised CHF 24.2 million in a first closing of its Series C round. This first closing was significantly oversubscribed by both existing and new investors from diverse geographies; BioVersys intends to complete the Series C investment round by the end of 2022.

The proceed will be used to initiate first Phase II clinical trials of BV100 and BVL-GSK098 and the preclinical development of BV200.

The Walder Wyss team includes Alexander Gutmans (Partner, Corporate/M&A and Venture Capital), Robert von Rosen (Partner, Corporate/M&A and Venture Capital), (Karina Tschon (Associate, Corporate/M&A and Venture Capital) as well as Lucas Maurer (Associate, Corporate/M&A and Venture Capital).

Technically necessary cookies

Essential technical cookies are necessary for the flawless functioning of our website and cannot be disabled.
Cookies for statistics

Analytical cookies enable us to count visits and traffic sources, allowing us to measure and enhance the performance of our website. They assist us in answering questions such as which pages are the most popular, which are the least used, and how visitors navigate the website. All information collected by these cookies is aggregated and therefore anonymous.
Marketing cookies may be set by our advertising partners on our website. These companies can use them to create a profile of your interests and display relevant advertisements on other websites. They operate by uniquely identifying your browser and device. By activating these cookies, you acknowledge and consent to the information collected by such cookies being sent to providers outside of Switzerland and the EU, including countries with (from the perspective of Swiss data protection law) inadequate data protection (e.g., the United States, Singapore, and Taiwan). You also acknowledge that data transmitted abroad is no longer protected by Swiss law, and foreign laws as well as regulatory orders may require the disclosure of this data to authorities and other third parties.

Marketing cookies may be set by our advertising partners on our website. These companies can use them to create a profile of your interests and display relevant advertisements on other websites. They operate by uniquely identifying your browser and device. By activating these cookies, you acknowledge and consent to the information collected by such cookies being sent to providers outside of Switzerland and the EU, including countries with (from the perspective of Swiss data protection law) inadequate data protection (e.g., the United States, Singapore, and Taiwan). You also acknowledge that data transmitted abroad is no longer protected by Swiss law, and foreign laws as well as regulatory orders may require the disclosure of this data to authorities and other third parties.